Encision Receives Technology Product of the Year Award
07 Giugno 2006 - 8:17PM
PR Newswire (US)
BOULDER, Colo., June 7 /PRNewswire-FirstCall/ -- Encision Inc.
(AMEX:ECI), a medical device company with patented surgical
technology emerging as a standard of care in minimally-invasive
surgery, announced that it was the recipient of the CSIA Apex Award
for Technology Product of the Year. Jack Serino, President &
CEO of Encision, accepted the award Tuesday evening, June 6, during
the "Spotlight on Innovation" ceremonies held at the Robert &
Judi Newman Center for the Performing Arts at the University of
Denver. "We are pleased that Encision's active electrode monitoring
technology has been recognized by the panel of 60 judges who
evaluated the many device, information and software technologies of
Colorado companies," said Jack Serino. CSIA is the leading trade
association representing the technology industry in Colorado,
providing connections, insight and competitive edge programs and
services, assisting more than 3,000 Colorado technology companies
to succeed and prosper. The mission of CSIA is to foster innovation
and a positive growth environment to enable the technology industry
in Colorado to compete on a global basis. Encision Inc. designs and
manufactures innovative surgical devices that allow the surgeon to
optimize technique and patient safety during a broad range of
surgical procedures. Based in Boulder, Colorado, the Company
pioneered the development of patented AEM(R) Laparoscopic
Instruments to improve electrosurgery and reduce the chance for
patient injury in minimally invasive surgery. In accordance with
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, the Company notes that statements in this press
release and elsewhere that look forward in time, which include
everything other than historical information, involve risks and
uncertainties that may cause actual results to differ materially
from those indicated by the forward- looking statements. Factors
that could cause the Company's actual results to differ materially
include, among others, its ability to increase revenues through the
Company's distribution channels, insufficient quantity of new
account conversions, insufficient cash to fund operations, scale up
production to meet delivery obligations, delay in developing new
products and receiving FDA approval for such new products and other
factors discussed in the Company's filings with the Securities and
Exchange Commission. CONTACT: Marcia McHaffie, Encision Inc.,
303-444-2600, DATASOURCE: Encision Inc. CONTACT: Marcia McHaffie of
Encision Inc., +1-303-444-2600,
Copyright
Grafico Azioni Encision (AMEX:ECI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Encision (AMEX:ECI)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Encision, (Borsa Americana (AMEX)): 0 articoli recenti
Più Encision Articoli Notizie